NO20072355L - Cupredoxinderiverte transportmidler og metoder for fremstilling av disse - Google Patents
Cupredoxinderiverte transportmidler og metoder for fremstilling av disseInfo
- Publication number
- NO20072355L NO20072355L NO20072355A NO20072355A NO20072355L NO 20072355 L NO20072355 L NO 20072355L NO 20072355 A NO20072355 A NO 20072355A NO 20072355 A NO20072355 A NO 20072355A NO 20072355 L NO20072355 L NO 20072355L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- cupredoxin
- preparation
- transport agents
- derived transport
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108010092351 cupredoxin Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Radiology & Medical Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Acoustics & Sound (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
Foreliggende oppfinnelse angir fremgangsmåter og materialer for levering av en cargoforbindelse inn i en cancercelle. Leveringen av cargoforbindelsen gjennomføres ved anvendelse av protein transduksjonsdoméne derivert fra cupredoxiner. Oppfinnelsen angir også fremgangsmåter for å behandle cancer og cancerdiagnostisering.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61678204P | 2004-10-07 | 2004-10-07 | |
US68050005P | 2005-05-13 | 2005-05-13 | |
US70029705P | 2005-07-19 | 2005-07-19 | |
PCT/US2005/035758 WO2006088508A2 (en) | 2004-10-07 | 2005-10-06 | Cupredoxin derived transport agents and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072355L true NO20072355L (no) | 2007-07-04 |
Family
ID=36916885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072355A NO20072355L (no) | 2004-10-07 | 2007-05-07 | Cupredoxinderiverte transportmidler og metoder for fremstilling av disse |
Country Status (17)
Country | Link |
---|---|
US (5) | US7691383B2 (no) |
EP (1) | EP1797114A4 (no) |
JP (2) | JP2008515428A (no) |
KR (1) | KR20070108128A (no) |
CN (1) | CN101437842A (no) |
AP (1) | AP2007003959A0 (no) |
AU (1) | AU2005327535A1 (no) |
BR (1) | BRPI0515850A (no) |
CA (1) | CA2582164A1 (no) |
CR (1) | CR9033A (no) |
EA (1) | EA200700813A1 (no) |
IL (1) | IL182202A0 (no) |
NO (1) | NO20072355L (no) |
TN (1) | TNSN07113A1 (no) |
UA (1) | UA97466C2 (no) |
WO (1) | WO2006088508A2 (no) |
ZA (1) | ZA200702855B (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7556810B2 (en) | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
US9096663B2 (en) | 2001-02-15 | 2015-08-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
US7691383B2 (en) | 2004-10-07 | 2010-04-06 | The Board Of Trustees Of The University Of Illinois | Cupredoxin derived transport agents and methods of use thereof |
US7301010B2 (en) * | 2001-02-15 | 2007-11-27 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating HIV infection with cupredoxin and cytochrome c |
US7618939B2 (en) | 2001-02-15 | 2009-11-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
DE602005005799T2 (de) * | 2004-02-23 | 2009-04-16 | Dow Global Technologies, Inc., Midland | Klebstoff auf wasserbasis zum kleben von substraten mit niedriger oberflächenenergie |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
US20090208476A1 (en) * | 2006-05-19 | 2009-08-20 | Tapas Das Gupta | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
US9434770B2 (en) * | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
US9598470B2 (en) * | 2004-10-07 | 2017-03-21 | Craig W. Beattie | Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways |
US8158574B2 (en) * | 2004-10-07 | 2012-04-17 | Cdg Therapeutics, Inc. | Compositions and methods to prevent cancer with cupredoxins |
US9968685B2 (en) | 2004-10-07 | 2018-05-15 | Brad N. Taylor | Methods to treat cancer with cupredoxins |
MX2008000994A (es) | 2005-07-19 | 2008-03-19 | Univ Illinois | Agentes de transporte para cruzar la barrera hematoencefalica y hacia el interior de las celulas de cancer cerebral, y metodos para el uso de los mismos. |
BRPI0615555A2 (pt) * | 2005-07-19 | 2009-07-14 | Univ Illinois | composições e métodos para o controle de angiogênese com cupredoxinas |
US20100278937A1 (en) * | 2005-10-06 | 2010-11-04 | Das Gupta Tapas K | Compositions and methods to prevent and/or treat cancer with pa-card |
US10266868B2 (en) * | 2006-05-19 | 2019-04-23 | The Board Of Trustees Of The University Of Illinois | Compositions for treating HIV infection with cupredoxin and cytochrome C |
JP2010502765A (ja) | 2006-09-11 | 2010-01-28 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシン由来ペプチドの修飾及びそれを使用する方法 |
EP2061498A4 (en) * | 2006-09-14 | 2009-11-04 | Univ Illinois | COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES |
US8017749B2 (en) * | 2006-12-04 | 2011-09-13 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
WO2008086523A2 (en) * | 2007-01-11 | 2008-07-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
RU2009133473A (ru) * | 2007-02-08 | 2011-03-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Композиции и способы для предотвращения рака с помощью купредоксинов |
PE20090446A1 (es) * | 2007-07-19 | 2009-05-06 | Biosigma Sa | Plasmidos para transformar una bacteria del genero acidithiobacillus spp. y metodo de transformacion |
PL2197903T3 (pl) * | 2007-09-04 | 2015-03-31 | Us Gov Health & Human Services | Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną |
WO2009078977A2 (en) * | 2007-12-14 | 2009-06-25 | Cdg Therapeutics Inc | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
EP3708682B1 (en) * | 2008-02-01 | 2022-11-23 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of medical diseases and conditions |
CA2736187A1 (en) * | 2008-09-05 | 2010-03-11 | Id Biomedical Corporation Of Quebec | Novel compositions and adjuvants |
JP2012518417A (ja) * | 2009-02-20 | 2012-08-16 | シーディージー セラピューティクス,インコーポレイテッド | Pa−cardを用いて癌を予防及び/又は治療するための組成物及び方法 |
EP3865590B1 (en) | 2009-09-09 | 2024-04-10 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
WO2011031877A1 (en) | 2009-09-09 | 2011-03-17 | The General Hospital Corporation | Use of microvesicles in analyzing nucleic acid profiles |
US8425662B2 (en) | 2010-04-02 | 2013-04-23 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
AU2011326366B2 (en) | 2010-11-10 | 2017-02-23 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
US20150241964A1 (en) * | 2014-02-11 | 2015-08-27 | Osterhout Group, Inc. | Eye imaging in head worn computing |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
WO2016176573A1 (en) | 2015-04-30 | 2016-11-03 | Board Of Regents, The University Of Texas System | Antibacterial polypeptide libraries and methods for screening the same |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827934A (en) | 1988-03-08 | 1998-10-27 | The University Of Wyoming | Cytotoxic diphtheria toxin fragments |
US5972899A (en) | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
JP3715745B2 (ja) * | 1997-06-17 | 2005-11-16 | ジーイー横河メディカルシステム株式会社 | 超音波撮像装置 |
ATE452185T1 (de) | 1999-01-26 | 2010-01-15 | Univ London | Dimethylarginin-dimethylaminohydrolasen |
US6800437B1 (en) * | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
US20020164703A1 (en) | 2000-12-21 | 2002-11-07 | Krzysztof Pawlowski | Card-domain containing polypeptides, encoding nucleic acids, and methods of use |
US7084105B2 (en) * | 2001-02-15 | 2006-08-01 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
US7691383B2 (en) | 2004-10-07 | 2010-04-06 | The Board Of Trustees Of The University Of Illinois | Cupredoxin derived transport agents and methods of use thereof |
US7338766B2 (en) * | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
US6708054B2 (en) * | 2001-04-12 | 2004-03-16 | Koninklijke Philips Electronics, N.V. | MR-based real-time radiation therapy oncology simulator |
JP4091318B2 (ja) * | 2002-03-04 | 2008-05-28 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | X線ct装置 |
GB0211295D0 (en) | 2002-05-16 | 2002-06-26 | Univ London | Treatment of pain |
JP2006502973A (ja) | 2002-05-20 | 2006-01-26 | ケムストップ ピーティーワイ リミテッド | 物質の調製および活性化のための工程ならびにそれを製造する手段 |
AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
US7322469B2 (en) | 2005-02-17 | 2008-01-29 | International Paper Company | Container for recording media |
JP2008539795A (ja) | 2005-05-20 | 2008-11-20 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法 |
JP2010502765A (ja) | 2006-09-11 | 2010-01-28 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシン由来ペプチドの修飾及びそれを使用する方法 |
EP2061498A4 (en) | 2006-09-14 | 2009-11-04 | Univ Illinois | COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES |
US8017749B2 (en) * | 2006-12-04 | 2011-09-13 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
RU2009133473A (ru) | 2007-02-08 | 2011-03-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Композиции и способы для предотвращения рака с помощью купредоксинов |
WO2009078977A2 (en) | 2007-12-14 | 2009-06-25 | Cdg Therapeutics Inc | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
-
2005
- 2005-10-06 US US11/244,105 patent/US7691383B2/en active Active
- 2005-10-06 AP AP2007003959A patent/AP2007003959A0/xx unknown
- 2005-10-06 EA EA200700813A patent/EA200700813A1/ru unknown
- 2005-10-06 WO PCT/US2005/035758 patent/WO2006088508A2/en active Application Filing
- 2005-10-06 EP EP05856923A patent/EP1797114A4/en not_active Withdrawn
- 2005-10-06 JP JP2007535767A patent/JP2008515428A/ja not_active Withdrawn
- 2005-10-06 CN CNA2005800415244A patent/CN101437842A/zh active Pending
- 2005-10-06 AU AU2005327535A patent/AU2005327535A1/en not_active Abandoned
- 2005-10-06 KR KR1020077007810A patent/KR20070108128A/ko not_active Application Discontinuation
- 2005-10-06 UA UAA200705048A patent/UA97466C2/ru unknown
- 2005-10-06 CA CA002582164A patent/CA2582164A1/en not_active Abandoned
- 2005-10-06 BR BRPI0515850-8A patent/BRPI0515850A/pt not_active IP Right Cessation
-
2007
- 2007-03-26 IL IL182202A patent/IL182202A0/en unknown
- 2007-03-28 TN TNP2007000113A patent/TNSN07113A1/en unknown
- 2007-03-30 CR CR9033A patent/CR9033A/es not_active Application Discontinuation
- 2007-04-05 ZA ZA200702855A patent/ZA200702855B/xx unknown
- 2007-05-07 NO NO20072355A patent/NO20072355L/no not_active Application Discontinuation
-
2010
- 2010-04-05 US US12/754,197 patent/US8206685B2/en active Active
-
2012
- 2012-06-25 US US13/531,832 patent/US8530635B2/en active Active
-
2013
- 2013-09-09 US US14/021,159 patent/US9161989B2/en active Active
-
2014
- 2014-05-07 JP JP2014096347A patent/JP2014204720A/ja active Pending
-
2015
- 2015-10-19 US US14/887,100 patent/US10239920B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10239920B2 (en) | 2019-03-26 |
TNSN07113A1 (en) | 2008-06-02 |
BRPI0515850A (pt) | 2008-08-12 |
US20160031947A1 (en) | 2016-02-04 |
CA2582164A1 (en) | 2006-08-24 |
US8206685B2 (en) | 2012-06-26 |
US7691383B2 (en) | 2010-04-06 |
ZA200702855B (en) | 2008-10-29 |
IL182202A0 (en) | 2007-07-24 |
CR9033A (es) | 2010-04-08 |
JP2008515428A (ja) | 2008-05-15 |
US9161989B2 (en) | 2015-10-20 |
EA200700813A1 (ru) | 2008-10-30 |
US20140037554A1 (en) | 2014-02-06 |
KR20070108128A (ko) | 2007-11-08 |
CN101437842A (zh) | 2009-05-20 |
US20100209355A1 (en) | 2010-08-19 |
WO2006088508A2 (en) | 2006-08-24 |
WO2006088508A3 (en) | 2008-12-24 |
AU2005327535A1 (en) | 2006-08-24 |
JP2014204720A (ja) | 2014-10-30 |
UA97466C2 (ru) | 2012-02-27 |
US20130011338A1 (en) | 2013-01-10 |
US8530635B2 (en) | 2013-09-10 |
EP1797114A4 (en) | 2009-07-15 |
EP1797114A2 (en) | 2007-06-20 |
US20060149037A1 (en) | 2006-07-06 |
AP2007003959A0 (en) | 2007-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072355L (no) | Cupredoxinderiverte transportmidler og metoder for fremstilling av disse | |
NO20063569L (no) | M-CSF-spesifikt monoklonalt antistoff og anvendelse derav | |
ATE549359T1 (de) | Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen | |
NZ596834A (en) | Prlr-specific antibody and uses thereof | |
ZA200701656B (en) | Humanized anti-cment antagonists | |
DK1874818T3 (da) | TGF-Beta 1-specifikke antistoffer | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
MX2007002675A (es) | Antagonistas anti-beta7 humanizados y usos para los mismos. | |
TNSN07264A1 (en) | Organic compounds | |
AU2007292902A8 (en) | Compositions and methods for enhancing transport through mucus | |
MY163480A (en) | Sclerostin binding agents | |
DE602005026556D1 (de) | Zusammensetzung zur proteasomhemmung | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
MX2009012838A (es) | Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo. | |
WO2006038208A3 (en) | Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment | |
MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения | |
UA88638C2 (ru) | Бета-карболины, полезные для лечения воспалительного заболевания | |
DE602005026962D1 (de) | Arylcarboxamide und ihre verwendung als antitumormittel | |
NO20083593L (no) | Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse | |
MX2009001341A (es) | Anticuerpos especificos de ephb3 y usos de los mismos. | |
WO2010099139A3 (en) | Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor | |
NO20075140L (no) | Fremgangsmater og preparater for modulering av vaskulaer integritet | |
ATE487721T1 (de) | Triaza-benzoäeüazulenderivate zur behandlung von tumoren | |
EA200702197A1 (ru) | Противораковая комбинация, содержащая производные замещённого акрилоилдистамицина и антитела, ингибирующие факторы роста или их рецепторы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |